Neuroprotective effects of aspirin in patients with acute cerebral infarction

Neuroscience Letters

Volumn 339, Issue 3, 2003, Pages 248-250

  Castillo, José ^a   Leira, Rogelio ^a   Moro, María Ángeles ^b   Lizasoain, Ignacio ^b   Serena, Joaquín ^c   Dávalos, Antoni ^c  

^a Instituto de Salud Carlos III   (Spain)

^b SCHOOL OF MEDICINE   (Spain)

^c HOSPITAL JOSEP TRUETA   (Spain)

Author keywords

Cerebrospinal fluid; Glutamate; Neuroprotection; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; GLUTAMIC ACID;

ADULT; AGED; ARTICLE; BRAIN INFARCTION; CEREBROSPINAL FLUID LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFECT; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; NEUROPROTECTION; PRIORITY JOURNAL; PROTEIN SECRETION; TREATMENT OUTCOME;

EID: 0037468581     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(03)00029-6     Document Type: Article

References (13)

1. Bezzi P., Carmignoto G., Pasti L., Vesce S., Rossi D., Rizzini B.L., Pozzan T., Volterra A. Prostaglandins stimulate calcium-dependent glutamate release in astrocytes. Nature. 391:1998;281-285.
2. Carolei A., Prencipe M., Fiorelli M., Fieschi C. Severity of stroke and aspirin. Neurology. 36:1986;1010-1011.
3. Castillo J., Dávalos A., Naveiro J., Noya M. Neuroexcitatory amino acids and their relationship to infarct size and neurological deficit in ischemic stroke. Stroke. 27:1996;1060-1065.
4. Castillo J., Dávalos A., Noya M. Progression of ischaemic stroke and excitotoxic amino acids. Lancet. 349:1987;79-83.
5. De Cristóbal J., Cárdenas A., Lizasoain I., Leza J.C., Fernández-Tomé P., Lorenzo P., Moro M.A. Inhibition of glutamate release via recovery of ATP levels accounts for a neuroprotective effect of aspirin in rat cortical neurons exposed to oxygen-glucose deprivation. Stroke. 33:2002;261-267.
6. De Cristóbal J., Moro M.A., Dávalos A., Castillo J., Leza J.C., Lorenzo P., Lizasoain I. Neuroprotective effect of aspirin by inhibition of glutamate release after permanent focal cerebral ischemia in rats. J. Neurochem. 79:2001;456-459.
7. Grilli M., Pizzi M., Memo M., Spano F. Neuroprotection by aspirin and sodium salicylate through blockade of NF-κB activation. Science. 274:1996;1383-1385.
8. Grotta J.C., Lemak N.A., Gary H., Fields W.S., Vital D. Does platelet antiaggregant therapy lessen the severity of stroke? Neurology. 35:1985;632-636.
9. Grotta J.C., Welch K.M.A., Fagan S.C., Lu M., Frankel M.R., Brott T., Levine S.R., Lyden P.D. Clinical deterioration following improvement in the NINDS rt-PA Stroke Trial. Stroke. 32:2001;661-668.
10. Joseph R., Han E., Tsering C., Grunfeld S., Welch K.M. Platelet activity and stroke severity. J. Neurol. Sci. 108:1992;1-6.
11. Moro M.A., De Alba J., Cárdenas A., De Cristóbal J., Leza J.C., Lizasoain I., Díaz-Guerra M.J.M., Boscá L., Lorenzo P. Mechanisms of the neuroprotective effect of aspirin after oxygen and glucose deprivation in rat forebrain slices. Neuropharmacology. 39:2000;1309-1318.
12. Patrono C. Aspirin as an antiplatelet drug. N. Engl. J. Med. 330:1994;1287-1294.
13. Serena J., Leira R., Castillo J., Pumar J.M., Castellanos M., Dávalos A. Neurological deterioration in acute lacunar infarction: the role of excitatory and inhibitory neurotransmitters. Stroke. 32:2001;1154-1161.